Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
WINDLAS.NS
Strong BuyPremium GrowerWindlas Biotech Limited · Healthcare · India · $248M · Avg Vol: $3M/d
84
StockRankGet insider-trade alerts
Q
67
V
33
M
82
P/E (TTM)
36.7x
ROE
11.4%
D/E
0.1x
Dividend %
0.6%
COMPANY DESCRIPTION
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 5.1B | 6.3B | 7.6B | 9.0B | 20.7% | 9.4B |
| EPS (INR) | 19.70 | 27.97 | 29.19 | 31.60 | 17.1% | 31.17 |
| Shares | 20.9M | 20.8M | 21.0M | 21.1M | +0.9% | 20.6M |
| Debt | 49.9M | 36.4M | 326.0M | 352.4M | 91.8% | 352.4M |
| Equity | 4.0B | 4.5B | 5.1B | 5.8B | 13.0% | — |
| Op CF | 609.6M | 1.1B | 681.9M | 1.0B | 19.8% | 1.0B |
| Inv CF | -141.1M | -920.7M | -740.6M | -917.9M | — | — |
| Fin CF | -437.4M | -152.9M | 10.1M | -130.3M | — | — |
Loading 1Y...
PRICE (1Y)+32.9%
SMA 50SMA 200
Close
$12.01
RSI (14)
85.1
52W High
$12.43
From 52W High
1.0%
SCORE BREAKDOWN
Quality
67
ROIC
15.7%84.5
ROE
11.4%74.5
GP/Assets
39.4%77.0
Op. Margin
7.8%58.1
FCF/Assets
4.1%65.9
Piotroski
431.0
Int. Cover
17.0x69.4
D/E Ratio
0.06x68.9
Current Ratio
1.95x38.0
Value
33
P/E (TTM)
36.7x32.4
EV/EBITDA
20.9x32.9
P/FCF
63.3x23.9
P/B
4.2x35.1
P/S
2.5x62.3
Div Yield
0.6%16.9
Momentum
82
52W High %
97%96.9
RS 6M
57%92.5
SMA 50/200
1.12x78.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
-0%36.8
FUNDAMENTALS
Market Cap
$248M
P/E (Forward)
—
Gross Margin
38.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of WINDLAS.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| WINDLAS.NS | Windlas Biotech Limited(you) | $248M | 84 | Strong Buy |
| SAKAR.NS | Sakar Healthcare Limited | $268M | 79 | Buy |
| INDSWFTLAB.NS | Ind-Swift Laboratories Limited | $356M | 81 | Strong Buy |
| SOLARA.NS | Solara Active Pharma Sciences Limited | $357M | 81 | Strong Buy |
| UNICHEMLAB.NS | Unichem Laboratories Limited | $413M | 87 | Strong Buy |
| AARTIDRUGS.NS | Aarti Drugs Limited | $406M | 80 | Strong Buy |
| HIKAL.NS | Hikal Limited | $320M | 75 | Buy |
| BETA.NS | Beta Drugs Limited | $228M | 72 | Buy |
| SYNCOMF.NS | Syncom Formulations (India) Limited | $208M | 96 | Strong Buy |
| VENUSREM.NS | Venus Remedies Limited | $229M | 99 | Strong Buy |
Peer medians: ROE 11.9% · P/E 42.8x · Gross margin 59.4%